SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals gains on plan to launch over 10 products in FY16

26 Aug 2015 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 1189.30, up by 1.25 points or 0.11% from its previous closing of Rs. 1188.05 on the BSE.

The scrip opened at Rs. 1188.05 and has touched a high and low of Rs. 1205.10 and Rs. 1156.55 respectively. So far 24993 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 677.85 on 26-Sep-2014.

Last one week high and low of the scrip stood at Rs. 1261.95 and Rs. 1076.60 respectively. The current market cap of the company is Rs. 33459.49 crore.

The promoters holding in the company stood at 46.44% while Institutions and Non-Institutions held 42.70% and 10.86% respectively.

Glenmark Pharmaceuticals (GPL) is planning to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes to report a growth of 18-20 percent. The company wants to increase its focus on the Indian market across four key areas, including dermatology, diabetes, cardiology and respiratory segments. The company derives about 26% of its revenues from the India, which is its second largest market.

GPL is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×